New combo attack on tough breast cancer shows promise
NCT ID NCT04837209
Summary
This study is testing whether a three-part treatment is safe and can help control advanced triple-negative breast cancer that has spread and hasn't responded well to standard immunotherapy. The treatment combines two drugs—one that helps the immune system fight cancer and another that stops cancer cells from repairing themselves—with standard radiation therapy. About 32 participants with this specific type of breast cancer will receive the treatment for up to 2 years to see if it can shrink tumors and slow the cancer's progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.